Home Health Care Steady Stock: ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)

Steady Stock: ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)


Shares of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) ended Wednesday session in red amid volatile trading. The shares closed down -0.23 points or -7.42% at $2.87 with 90624 shares getting traded. Post opening the session at $2.91, the shares hit an intraday low of $2.81 and an intraday high of $3.05 and the price vacillated in this range throughout the day.

Market Cap/Outstanding Shares

The company has a market cap of $8.94 million and the number of outstanding shares have been calculated to be 3.44 million shares.

Performance weekly/monthly/quarterly/yearly in percentage (%)

The performance for the week is valued at 4021.43%, resulting in a performance for the month at 2770.65%. Therefore, the stated figure displays a quarterly performance of 2300.17% and an annual performance of 569.22% traded down -7.42% on 23 November, 2016 hitting $2.87.

EPS (Earning Per Share )

The EPS of IMUC is strolling at -0.21, measuring its EPS growth this year at 6.30%. As a result, the company has an EPS growth of 10.00% for the approaching year. Company’s EPS for the past five years is valued at 19.30%.


Beta factor is stands at 1.00 and Avg. true range is 0.28. Historically, the volatility of this stock is about 17.34% a week and 13.10% a month.

ImmunoCellular Therapeutics Ltd (IMUC) recently declared financial results for the third quarter of 2016.

Third Quarter 2016 Financial Results

For the quarter ended September 30, 2016, ImmunoCellular incurred a net loss of $4.8 million, or $0.04 per basic and diluted share, contrast to a net loss of $3.4 million, or $0.04 per basic and diluted share, for the quarter ended September 30, 2015.

During the third quarter 2016, ImmunoCellular incurred $4.6 million of research and development expenses contrast to $2.7 million in the prior year quarter, while general and administrative expenses reduced to $908,000 contrast to $1.1 million in the prior year. The $1.9 million increase in research and development expenses mainly reflects the additional expenses associated with the phase 3 trial of ICT-107. The decrease in general and administrative expenses reflects lower professional fees in the current quarter.

The loss for the current quarter was partially offset by a $1.1 million credit to other income to reflect a reduction in the valuation of the Company’s warrant derivative liabilities.  In the same quarter of the prior year, the Company recorded a corresponding credit of $339,000.